<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648724</url>
  </required_header>
  <id_info>
    <org_study_id>Sym015-01</org_study_id>
    <secondary_id>2016-003912-11</secondary_id>
    <nct_id>NCT02648724</nct_id>
  </id_info>
  <brief_title>Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies</brief_title>
  <official_title>An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study to test Sym015 in humans. The primary purpose of this study is to see
      if Sym015 is safe and effective for patients with advanced solid tumors who do not have other
      available or accessible treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for safety
      and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be determined.
      Sym015 will be given at different dose levels on an every second week (Q2W) dosing schedule.
      Each patient will be given one fixed dose level.

      In the second part of the study (Part 2, dose-expansion), dosing will be at the RP2D on a Q2W
      dosing schedule. Two cohorts will be included:

        -  Basket Cohort: Patients with KRAS wild-type (WT) advanced solid tumor malignancies with
           MET-amplification and without therapeutic options. Patients must have no prior therapy
           with MET-targeting agents, except a subset of patients having received prior therapy
           with a MET-targeting tyrosine kinase inhibitor (TKI).

        -  Non-Small Cell Lung Carcinoma (NSCLC) Cohort: Patients with KRAS WT NSCLC with MET exon
           14 skipping (METex14) mutation and without therapeutic options. Patients do not need to
           be MET-amplified and may have received prior therapy with a MET-targeting TKI. Patients
           with malignancies other than NSCLC may be considered for entry to this cohort following
           discussion with the Sponsor's Medical Monitor(s).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Assess the safety and tolerability of Sym015 on a Q2W schedule.</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration on a Q2W dosing schedule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D.</measure>
    <time_frame>24 months</time_frame>
    <description>Documented objective response (OR) (defined as partial response [PR] or complete response [CR]) in the Basket Cohort, assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Determine a Q2W RP2D of Sym015.</measure>
    <time_frame>12 Months</time_frame>
    <description>Determination based on an evaluation of the patient data for DLTs from Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Evaluate the immunogenicity of Sym015.</measure>
    <time_frame>36 Months</time_frame>
    <description>Serum sampling to assess the potential for anti-drug antibody (ADA) formation. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Evaluate potential biomarkers of Sym015 action, and estimate, if feasible, the magnitude of biological activity.</measure>
    <time_frame>36 Months</time_frame>
    <description>Potential biomarkers of interest include genes, gene transcripts and proteins of the receptor tyrosine kinases (RTKs) and molecules of the MET signaling pathway. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Area under the concentration-time curve in a dosing interval (AUC)</measure>
    <time_frame>36 Months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Maximum concentration (Cmax)</measure>
    <time_frame>36 months</time_frame>
    <description>Will be derived from observed data. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Time to reach maximum concentration (Tmax)</measure>
    <time_frame>36 Months</time_frame>
    <description>Will be derived from observed data. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Trough concentration (Ctrough)</measure>
    <time_frame>36 Months</time_frame>
    <description>Will be derived from observed data. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Elimination half-life (TÂ½)</measure>
    <time_frame>36 Months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Clearance (CL)</measure>
    <time_frame>36 Months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual time points. For Part 2, this applies to both the Basket Cohort and the NSCLC Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Additional preliminary evaluation of the antitumor activity of Sym015 when administered at the Q2W RP2D.</measure>
    <time_frame>36 Months</time_frame>
    <description>This applies to the NSCLC Cohort. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Oncology</condition>
  <condition>MET Gene Amplification</condition>
  <condition>NSCLC</condition>
  <condition>MET Gene Mutation</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose-Escalation (Phase 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym015 will be tested in four dose titration cohorts. A substitute or an additional dose level could potentially be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Basket Cohort (Phase 2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with KRAS WT advanced solid tumor malignancies with MET-amplification will receive Sym015 at the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: NSCLC Cohort (Phase 2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with KRAS WT NSCLC with METex14 mutation will receive Sym015 at the RP2D.
Note: Patients with malignancies other than NSCLC may be considered for entry to this cohort following discussion with the Sponsor's Medical Monitor(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym015</intervention_name>
    <description>Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.</description>
    <arm_group_label>Part 1: Dose-Escalation (Phase 1a)</arm_group_label>
    <arm_group_label>Part 2: Basket Cohort (Phase 2a)</arm_group_label>
    <arm_group_label>Part 2: NSCLC Cohort (Phase 2a)</arm_group_label>
    <other_name>Anti-MET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main inclusion criteria all patients, Part 1 and Part 2:

          -  Male or female, at least 18 years of age at the time of informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Life expectancy &gt;3 months assessed during Screening

          -  Documented (histologically- or cytologically-proven) solid tumor malignancy that is
             locally advanced or metastatic, and that is refractory to standard therapy or for
             which no standard therapy is available or accessible

          -  Tumor documented to be KRAS WT by local assessment (i.e. the tumor must express the
             KRAS WT, exon 2, 3 and 4)

        Additional main inclusion criteria applicable to Part 2 ONLY:

          -  Measurable disease according to RECIST v1.1 that has been confirmed by computed
             tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle
             1/Day 1 (C1/D1)

          -  Tumor documented to be KRAS WT by local assessment according to institutional
             standards.

          -  Basket Cohort ONLY:

               -  Confirmed MET-amplification by local assessment

               -  No prior therapy with MET-targeting agents (except a subset of patients having
                  received prior therapy with a MET-targeting TKI)

               -  Willingness to undergo a pre- and post-dosing biopsy (maximum of 2 biopsies) from
                  primary or metastatic tumor site(s) considered safely accessible for biopsy

          -  NSCLC Cohort ONLY:

               -  Documented METex14 mutations (patients need not be MET-amplified and may have
                  received prior therapy with a MET-targeting TKI). Patients with malignancies
                  other than NSCLC may be considered for entry to this cohort following discussion
                  with the Sponsor's Medical Monitor(s).

        Exclusion Criteria:

        Main exclusion criteria all patients, Part 1 and Part 2:

          -  Any antineoplastic agent for the primary malignancy (standard or investigational)
             without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest,
             prior to C1/D1, except: nitrosoureas and mitomycin C within 6 weeks prior to C1/D1

          -  Immunosuppressive or systemic hormonal therapy within 2 weeks prior to C1/D1 with
             specified allowed exceptions

          -  Use of hematopoietic growth factors within 2 weeks prior to C1/D1

          -  Active second malignancy or history of another malignancy within the last 3 years,
             with specified allowed exceptions

          -  Central nervous system (CNS) malignancy including primary malignancies of the CNS
             and/or known, untreated CNS or leptomeningeal metastases, or spinal cord compression;
             patients with any of these not controlled by prior surgery or radiotherapy, or
             symptoms suggesting CNS involvement for which treatment is required

          -  Inadequate recovery from an acute toxicity associated with any prior antineoplastic
             therapy

          -  Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any
             prior surgical procedure

          -  Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within
             1 month prior to C1/D1, unless adequately treated and stable

          -  Active uncontrolled bleeding or a known bleeding diathesis

          -  Significant cardiovascular disease or condition

          -  Abnormal hematologic, renal or hepatic function

        Additional main exclusion criteria applicable to Part 2 ONLY:

          -  Prior therapy with MET-inhibiting agents (exceptions will be a subset of patients that
             will be entered to the Basket Cohort after having received prior therapy with a
             MET-targeting TKI, and patients entered to the NSCLC Cohort who may have received
             prior therapy with a MET-targeting TKI)

          -  Prior therapy with antibody to hepatocyte growth factor (HGF)

          -  Basket Cohort ONLY: Tumor status demonstrating MET-polysomy in the absence of
             MET-amplification, as specified. Patients in the NSCLC Cohort with polysomy are
             eligible.

          -  Radiotherapy against target lesions within 4 weeks prior to C1/D1, unless there is
             documented progression of the lesion following the radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amita Patnaik, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulla Holm Hansen, RN</last_name>
    <phone>+45 2487 0020</phone>
    <email>uhh@symphogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Horak, MD</last_name>
    <phone>+45 2055 2604</phone>
    <email>idh@symphogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Catenacci, MD</last_name>
      <phone>773-702-7596</phone>
      <email>dcatenac@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shadia Jalal, MD</last_name>
      <email>sjalal@Iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Shadia Jalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Braiteh, MD</last_name>
      <phone>702-952-3400</phone>
      <email>fadi.braiteh@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Eads, MD</last_name>
      <phone>216-844-6031</phone>
      <email>Jennifer.Eads@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Eads, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Janku, MD, PhD</last_name>
      <phone>713-563-2632</phone>
      <email>fjanku@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik, MD, FRCP(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristoffer Staal Rohrberg, MD, PhD</last_name>
      <phone>+45 3545 6353</phone>
      <email>kristoffer.staal.rohrberg@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Kristoffer Staal Rohrberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Chung Cheung Yau, MD</last_name>
      <phone>+85 2 2855 3725</phone>
      <email>tyaucc@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Thomas Chung Cheung Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Wha Moon, MD, PhD</last_name>
      <phone>+82 3 1780 3436</phone>
      <email>ymoon@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Wha Moon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Cheol Chung, MD, PhD</last_name>
      <phone>+82 2 2228 8132</phone>
      <email>unchung8@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyun Cheol Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <phone>+82 2 3010 3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hei-Cheul Jeung, MD, PhD</last_name>
      <phone>+ 82 2 2019 3297</phone>
      <email>jeunghc1123@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hei-Cheul Jeung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeeyun Lee, MD, PhD</last_name>
      <phone>+82 2 3410 1779</phone>
      <email>jyunlee@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Jeeyun Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Cheul Oh, MD, PhD</last_name>
      <phone>+82 2 2626 3060</phone>
      <email>sachoh@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Cataluna</state>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Martinez Bueno, MD</last_name>
      <phone>+34 93 546 0135</phone>
      <email>amartinez@oncorosell.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Martinez Bueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda Cabanas, MD</last_name>
      <phone>+34 93 274 6000</phone>
      <phone_ext>4910</phone_ext>
      <email>egarralda@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Elena Garralda Cabanas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Garcia Corbacho, MD</last_name>
      <email>garcia33@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Javier Garcia Corbacho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar Lopez Criado, MD</last_name>
      <phone>+34 91 787 8600</phone>
      <email>mplopez@mdanderson.es</email>
    </contact>
    <investigator>
      <last_name>Maria Pilar Lopez Criado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Fang Chiu, MD, PhD</last_name>
      <phone>+886 4 2205 2121</phone>
      <phone_ext>5051</phone_ext>
      <email>d5686@mail.cmuh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chang-Fang Chiu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shang-Yin Wu, MD</last_name>
      <phone>+886 2 235 3535</phone>
      <phone_ext>4620</phone_ext>
      <email>wushangyin@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Shang-Yin Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Her-Shyong Shiah, MD</last_name>
      <phone>+886 2 2737 2181</phone>
      <email>121010@h.tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Her-Shyong Shiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Liang Ho, MD</last_name>
      <phone>+886 2 8792 7208</phone>
      <email>hochingliang@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Ching-Liang Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor Malignancies</keyword>
  <keyword>MET Gene Amplification</keyword>
  <keyword>MET Amplification</keyword>
  <keyword>Wild-type</keyword>
  <keyword>NSCLC</keyword>
  <keyword>METex14</keyword>
  <keyword>Non-Small Cell Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

